Disease · MONDO_0016367
Comparisons in its trials45
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 45
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8 | 14 of 96 | 21 of 104 | 200 | NCT00106184 | Trial comparisons |
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): 20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI]) | 14 of 96 | 21 of 104 | 200 | NCT00106184 | Trial comparisons |
| Treatment Group A vs Treatment Group B: serious adverse events | 24 of 96 | 41 of 104 | 200 | NCT00106184 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: deaths from any cause | 0 of 95 | 0 of 48 | 143 | NCT02728752 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: serious adverse events | 14 of 95 | 2 of 48 | 143 | NCT02728752 | Trial comparisons |
| Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | 37 of 47 | 21 of 48 | 95 | NCT02728752 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With CDASI Response (>=7-point Improvement) at Week 26 | 6 of 26 | 4 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With Clinical Worsening (CW) During the RCP At 2 Consecutive Visits | 2 of 26 | 0 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With ≥ 20-Point Improvement Response on IMACS-TIS (TIS20) Response at Week 26 | 14 of 26 | 9 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With Response Related to Muscle Enzymes: Normalization of Most Abnormal Baseline Enzyme at Week 26 | 4 of 26 | 1 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With ≥ 60-Point Improvement Response on IMACS-TIS (TIS60) Response at Week 26 | 3 of 26 | 2 of 12 | 38 | NCT04999020 | Trial comparisons |
RCP: Ravulizumab vs RCP: Placebo: Number of Participants With International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS-TIS) (TIS40) Response at Week 26 of the Randomized Controlled Period | 9 of 26 | 6 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants Who Received Acute Rescue Therapy With Standard DM Treatment | 2 of 26 | 0 of 12 | 38 | NCT04999020 | Trial comparisons |
| RCP: Ravulizumab vs RCP: Placebo: Number of Participants With Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) Response at Week 26 | 5 of 26 | 2 of 12 | 38 | NCT04999020 | Trial comparisons |
| Group A: Tocilizumab vs Group B: Placebo: deaths from any cause | 0 of 18 | 0 of 18 | 36 | NCT02043548 | Trial comparisons |
| Group A: Tocilizumab vs Group B: Placebo: serious adverse events | 1 of 18 | 0 of 18 | 36 | NCT02043548 | Trial comparisons |
| 1 Prednison vs 2 Prednison Methotrexate: serious adverse events | 4 of 16 | 5 of 15 | 31 | NCT00651040 | Trial comparisons |
| BAF312/BAF312 vs Placebo/BAF312: deaths from any cause | 0 of 16 | 0 of 10 | 26 | NCT01148810 | Trial comparisons |
| BAF312/BAF312 vs Placebo/BAF312: serious adverse events | 0 of 16 | 3 of 10 | 26 | NCT01148810 | Trial comparisons |
| JBT-101 vs Placebo: deaths from any cause | 0 of 11 | 0 of 11 | 22 | NCT02466243 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016367/comparisons